Efficacy of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial Amsterdam, KETA)

This ongoing EEA CTA trial (n=128) conducted in the Netherlands by the Academic Medical Center (AMC) investigates the efficacy of intranasal ketamine in addressing acute suicidality (SI).

Referred to as the Ketamine Trial Amsterdam (KETA), the trial involves a double-blind, randomized, placebo-controlled design. The primary objective is to examine the anti-suicidal effects of a single dose of intranasal ketamine in acutely suicidal subjects, assessing changes in suicidality scores on the Beck Scale for Suicide Ideation (BSSI). Secondary objectives include safety, antidepressant effects, time-course of effects, and neurobiological markers measured through various imaging techniques and blood samples.

The trial involves adults aged 18-70, excludes those with specific conditions, and has a duration of approximately 3 years. The last follow-up call for the last subject is expected one week after their visit. The trial received authorization from the Competent Authority on November 6, 2018, and a favourable ethics committee opinion on July 23, 2018.

Topic Suicidality
Compound Ketamine Placebo
Country Netherlands
Visit trial
Status Active, not recruiting
Results Published No
Start date 23 July 2018
End date 30 December 2024
Phase Phase II
Design Blinded
Type Interventional
Generation First
Participants 128
Sex All
Age 18- 70
Therapy Yes

Trial Details

The ongoing Ketamine Trial Amsterdam (KETA) in the Netherlands, sponsored by the Academic Medical Center (AMC), is a double-blind, placebo-controlled study investigating intranasal ketamine's efficacy in treating acute suicidality (n=128). The trial aims to assess anti-suicidal effects and neurobiological markers over approximately 3 years. Authorized by the Competent Authority on November 6, 2018, with a favourable ethics committee opinion on July 23, 2018.

NCT Number 2015-004745-70

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.